Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Amanda A. van Vliet"'
Autor:
Amanda A. van Vliet, Ella Peters, Denise Vodegel, Daniëlle Steenmans, Monica Raimo, Susan Gibbs, Tanja D. de Gruijl, Adil D. Duru, Jan Spanholtz, Anna-Maria Georgoudaki
Publikováno v:
iScience, Vol 26, Iss 7, Pp 107078- (2023)
Summary: Umbilical cord blood (UCB) CD34+ progenitor cell-derived natural killer (NK) cells exert efficient cytotoxicity against various melanoma cell lines. Of interest, the relative cytotoxic performance of individual UCB donors was consistent thro
Externí odkaz:
https://doaj.org/article/d1425338c1d4414a97480c3edb937771
Autor:
Tanmoy Saha, Amanda A. van Vliet, Chunxiao Cui, Jorge Jimenez Macias, Arpita Kulkarni, Luu Nhat Pham, Sean Lawler, Jan Spanholtz, Anna-Maria Georgoudaki, Adil Doganay Duru, Aaron Goldman
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Allogeneic natural killer (aNK) cell adoptive therapy has the potential to dramatically impact clinical outcomes of glioblastoma multiforme (GBM). However, in order to exert therapeutic activity, NK cells require tumor expression of ligands for activ
Externí odkaz:
https://doaj.org/article/e47ed6b00c7f48eaa54b2fa0f80f11a6
Publikováno v:
Cancers, Vol 13, Iss 18, p 4722 (2021)
Adoptive cell therapy (ACT) represents a promising alternative approach for patients with treatment-resistant metastatic melanoma. Lately, tumor infiltrating lymphocyte (TIL) therapy and chimeric antigen receptor (CAR)-T cell therapy have shown impro
Externí odkaz:
https://doaj.org/article/b1b8a30e55fc46e197e7930419a61e00
Autor:
Tanja D de Gruijl, Jurriaan Tuynman, Jan Spanholtz, Hans J van der Vliet, Elisa C Toffoli, Amanda A van Vliet, Henk W M Verheul
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Introduction Natural killer (NK) cells are innate lymphocytes with a key role in the defense against tumors. Recently, allogeneic NK cell-based therapies have gained interest because of their ability to directly lyse tumor cells without inducing graf
Externí odkaz:
https://doaj.org/article/fb317fc654cf49d78d04ecfc9bd6d9e7
Autor:
Hans van Vliet, Tanja D. de Gruijl, Henk M.W. Verheul, Lisa A. King, Roeland Lameris, Abdolkarim Sheikhi, Bruce Walcheck, Elisa C. Toffoli, Jan Spanholtz, Jurriaan B. Tuynman, Amanda A. van Vliet
Publikováno v:
Cancers
Volume 13
Issue 21
Toffoli, E C, Sheikhi, A, Lameris, R, King, L A, van Vliet, A, Walcheck, B, Verheul, H M W, Spanholtz, J, Tuynman, J, de Gruijl, T D & van der Vliet, H J 2021, ' Enhancement of nk cell antitumor effector functions using a bispecific single domain antibody targeting cd16 and the epidermal growth factor receptor ', Cancers, vol. 13, no. 21, 5446 . https://doi.org/10.3390/cancers13215446
Cancers, Vol 13, Iss 5446, p 5446 (2021)
Cancers, 13(21):5446. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13
Cancers, 13, 21
Volume 13
Issue 21
Toffoli, E C, Sheikhi, A, Lameris, R, King, L A, van Vliet, A, Walcheck, B, Verheul, H M W, Spanholtz, J, Tuynman, J, de Gruijl, T D & van der Vliet, H J 2021, ' Enhancement of nk cell antitumor effector functions using a bispecific single domain antibody targeting cd16 and the epidermal growth factor receptor ', Cancers, vol. 13, no. 21, 5446 . https://doi.org/10.3390/cancers13215446
Cancers, Vol 13, Iss 5446, p 5446 (2021)
Cancers, 13(21):5446. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13
Cancers, 13, 21
Simple Summary Strategies to enhance the preferential accumulation and activation of Natural Killer (NK) cells in the tumor microenvironment can be expected to increase the efficacy of NK cell-based cancer immunotherapy. In this study, we report that
Publikováno v:
Cancers
van Vliet, A A, Georgoudaki, A M, Raimo, M, de Gruijl, T D & Spanholtz, J 2021, ' Adoptive nk cell therapy : A promising treatment prospect for metastatic melanoma ', Cancers, vol. 13, no. 18, 4722 . https://doi.org/10.3390/cancers13184722
Cancers, Vol 13, Iss 4722, p 4722 (2021)
van Vliet, A A, Georgoudaki, A M, Raimo, M, de Gruijl, T D & Spanholtz, J 2021, ' Adoptive nk cell therapy : A promising treatment prospect for metastatic melanoma ', Cancers, vol. 13, no. 18, 4722 . https://doi.org/10.3390/cancers13184722
Cancers, Vol 13, Iss 4722, p 4722 (2021)
Simple Summary The incidence of metastatic melanoma has been increasing over the past years with current therapies showing limited efficacy to cure the disease. Therefore, other options are being investigated, such as adoptive cell therapy (ACT) wher
Autor:
Toffoli EC; Amsterdam Infection and Immunity Institute, Cancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands., Sheikhi A; Amsterdam Infection and Immunity Institute, Cancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.; School of Medicine, Dezful University of Medical Sciences, Department of Immunology, Dezful 64616-43993, Iran., Lameris R; Amsterdam Infection and Immunity Institute, Cancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands., King LA; Amsterdam Infection and Immunity Institute, Cancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands., van Vliet A; Glycostem Therapeutics, 5349 AB Oss, The Netherlands., Walcheck B; Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN 55108, USA., Verheul HMW; Radboud Institute for Health Sciences, Department of Medical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands., Spanholtz J; Glycostem Therapeutics, 5349 AB Oss, The Netherlands., Tuynman J; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Surgery, 1081 HV Amsterdam, The Netherlands., de Gruijl TD; Amsterdam Infection and Immunity Institute, Cancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands., van der Vliet HJ; Amsterdam Infection and Immunity Institute, Cancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.; Lava Therapeutics, 3584 CM Utrecht, The Netherlands.
Publikováno v:
Cancers [Cancers (Basel)] 2021 Oct 29; Vol. 13 (21). Date of Electronic Publication: 2021 Oct 29.